Literature DB >> 786685

The serum level approach to individualization of drug dosage.

J Koch-Weser.   

Abstract

The importance of individualizing the dosage of potent drugs in order to maximize their therapeutic effectiveness and safety is generally accepted. Whenever possible the dosage of a drug should be "titrated" directly in each patient against the intensity of its therapeutic or toxic actions. Unfortunately, for many drugs convenient clinical yardsticks of the intensity of their pharmacologic effects are lacking. Determination of the serum concentration of such compounds can help to guide adjustment of dosage during their therapeutic use. By measuring the serum level of drugs one bypasses the largest source of individual differences in dose-effect relationships-the pharmacokinetic variation between subjects. However, the relationship between the serum concentration of a drug and the intensity of its pharmacodynamic action is influenced by many other factors, which must always be considered in interpretation of serum levels. Therapeutic decisions should never be based soley on the serum concentration of a compound, nor can such measurements ever substitute for careful medical observation and judgement.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 786685     DOI: 10.1007/bf00613423

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

Review 1.  Pharmacodynamic and pharmacokinetic measurements of antiepileptic drugs.

Authors:  H Kutt
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

Review 2.  Factors causing interindividual variations of drug concentrations in blood.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

Review 3.  Salicylate intoxication.

Authors:  J B Hill
Journal:  N Engl J Med       Date:  1973-05-24       Impact factor: 91.245

4.  Drug therapy: patient compliance.

Authors:  B Blackwell
Journal:  N Engl J Med       Date:  1973-08-02       Impact factor: 91.245

5.  Quinidine elimination in patients with congestive heart failure or poor renal function.

Authors:  K M Kessler; D T Lowenthal; H Warner; T Gibson; W Briggs; M M Reidenberg
Journal:  N Engl J Med       Date:  1974-03-28       Impact factor: 91.245

6.  Influence of serum digoxin concentration measurements on frequency of digitoxicity.

Authors:  J Koch-Weser; D W Duhme; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

7.  Relation of hydralazine plasma concentration to dosage and hypotensive action.

Authors:  R Zacest; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

8.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

Review 9.  Serum digitalis measurements in the assessment of digitalis resistance and sensitivity.

Authors:  V P Butler; J Lindenbaum
Journal:  Am J Med       Date:  1975-04       Impact factor: 4.965

10.  Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program.

Authors:  D W Duhme; D J Greenblatt; J Koch-Weser
Journal:  Ann Intern Med       Date:  1974-04       Impact factor: 25.391

View more
  23 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

Review 2.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Prediction of digoxin dose requirements.

Authors:  S M Dobbs; G E Mawer
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 4.  Drug pharmacokinetics in the postoperative period.

Authors:  J Elfstrom
Journal:  Clin Pharmacokinet       Date:  1979 Jan-Feb       Impact factor: 6.447

5.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 6.  Clinical pharmacology in the last decade.

Authors:  P Turner
Journal:  Postgrad Med J       Date:  1981-08       Impact factor: 2.401

Review 7.  Plasma concentrations in the control of drug therapy.

Authors:  L B Jellett
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 8.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 9.  Clinical pharmacokinetics of digoxin in infants.

Authors:  G Wettrell; K E Andersson
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

10.  Factors influencing blood concentrations of chlordiazepoxide: a use of multiple regression analysis.

Authors:  D J Greenblatt; J S Harmatz; D R Stanski; R I Shader; K Franke; J Koch-Weser
Journal:  Psychopharmacology (Berl)       Date:  1977-11-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.